Thomas Garner - 06 Mar 2026 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, Chief Commercial Officer
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
06 Mar 2026
Net transactions value
$0
Form type
4
Filing time
10 Mar 2026, 18:00:13 UTC
Previous filing
10 Dec 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Garner Thomas EVP, Chief Commercial Officer C/O ACADIA PHARMACEUTICALS, INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO /s/ Jennifer J. Rhodes, Attorney-in-Fact 10 Mar 2026 0001996325

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award +97,947 $0.000000* 97,947 06 Mar 2026 Common Stock 97,947 $22.16 Direct F1
transaction ACAD Restricted Stock Units Award +28,493 $0.000000* 28,493 06 Mar 2026 Common Stock 28,493 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F3 The restricted stock units vest in four equal annual installments beginning March 6, 2027.